▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Amarin Plc (NASDAQ: AMRN)

$10.97

(0.6%)

$0.07

Price as of May 20, 2025, 10:38 a.m. ET

Amarin Plc Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
AMRN	-37.36%	-92.69%	-40.74%	-100%
S&P	+12.45%	+100.69%	+14.95%	+1,224%

Amarin Plc Company Info

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

News & Analysis

The Fool has written over 500 articles on Amarin Plc.

Featured Article

Why Amarin Stock Was Rocketing Higher on Wednesday

There was unambigously good news about the company's single commercialized medication.

Eric Volkman | Apr 3, 2024

Featured Article

Why Amarin Stock Skyrocketed Today

The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.

Steve Symington | Jan 10, 2024

Why Amarin Stock Is Sinking Today

Keith Speights | Jul 19, 2023

The drugmaker announced a major corporate reorganization and a new CEO.

Why Amarin Stock Tumbled This Week

George Budwell | Jan 20, 2023

Amarin's tussle with its largest stakeholder doesn't appear to be sitting well with shareholders.

Why Amarin Stock Was a Winner Today

Eric Volkman | Nov 15, 2022

The product most readily identified with the company will soon hit pharmacy shelves in Australia.

Why Amarin Stock Was Plunging This Week

Eric Volkman | Aug 26, 2022

Investors weren't happy with the company's decision to cease operations in a large country.

Why Investors Were Giving Amarin the Cold Shoulder Today

Eric Volkman | Aug 3, 2022

Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.

Why Amarin Stock Dipped This Week

George Budwell | Jul 15, 2022

The drugmaker's downward spiral continued.

Valuation

Podcast Episodes

20191120 If Healthcare_thumbnail

Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?

Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.

Todd Campbell | Nov 22, 2019

Earnings Transcripts

Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript

AMRN earnings call for the period ending December 31, 2024.

Motley Fool Transcribing | Mar 12, 2025

Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript

AMRN earnings call for the period ending September 30, 2024.

Motley Fool Transcribing | Oct 31, 2024

Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript

AMRN earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Jul 31, 2024

Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript

AMRN earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 1, 2024

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services